Glucagon-like peptide-1 (GLP-1): A trial of treatment in non-insulin- dependent diabetes mellitus

European Journal of Clinical Investigation

Volumn 27, Issue 6, 1997, Pages 533-536

  Todd, J F ^a   Wilding, J P H ^a   Edwards, C M B ^a   Khan, F A ^a   Ghatei, M A ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; Glucagon like peptide 1 (7 36) amide; Incretin; Non insulin dependent diabetes mellitus; Treatment

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TEST MEAL;

EID: 0030754176     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1490691.x     Document Type: Article

References (10)

1. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscope immunohistochemistry. J Histochem Cytochem 1985;33:1080-6.
2. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4.
3. Fehmann HC, Goke R, Goke B. Glucagon-like peptide-1 (7-37)/ (7-36) amide is new incretin. Mol Cell Endocrinol 1992;85:C39-44.
4. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
5. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide enhances glucose tolerance both by stimulation of insulin release and by increasing insulin independent glucose disposal. J Clin Invest 1994;93:2263-6.
6. Gutniak MK, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes post-prandial glycaemia in patients with NIDDM. Diabetes Care 1994;17:1039-44.
7. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck M. Gastric emptying, glucose responses and insulin secretion after liquid test meal: elects of exogenous gucagon-like peptide (GLP-1) (7-36) amide in patients with type-2 (noninsulin-dependent) diabetes mellitus. J Clin Endo Metab 1996;81:327-32.
8. Holz GG 4th, Kuhtreiber WN, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993;361:362-5.
9. Gutniak MK, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide 1 (7-36) amide in normal subjects and patients with diabetes. N Engl J Med 1942;326:1316-22.
10. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 1996;19:843-8.